Bayer stock gains support from Barclays upgrade and deleveraging targets

Published on 09/09/2026 at 14:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer stock has risen about 33.0 percent year to date, with Barclays lifting its price target to EUR 70 on September 9, 2026. The shares recently closed around EUR 49.30, as investors focus on debt reduction and cash flow guidance.

Forscherin im weißen Kittel pipettiert an einem beleuchteten Laborarbeitsplatz vor einem Bildschirm mit 3D-Molekülstruktur — Pharmazeutisches Forschungslabor – Wissenschaftlerin mit Pipette, Molekülstruktur-Monitor, blaue LED-Beleuchtung, Illustration mit AI erstellt.

Bayer AG stock (ISIN DE000BAY0017) is trading around the EUR 49 mark on Xetra as of September 9, 2026, after a year-to-date gain of about 33.0 percent that has drawn renewed analyst attention to the Leverkusen-based group’s deleveraging and cash flow targets.

Barclays lifts Bayer price target on leverage progress

According to Ad-hoc-news on September 9, 2026, Barclays raised its price target for Bayer stock from EUR 60 to EUR 70 while reiterating an Overweight rating, placing the new target roughly 42 percent above a recent closing level of EUR 49.33.

In the same overview, Ad-hoc-news reports that JPMorgan currently maintains a price target of EUR 61 and UBS one of EUR 62, both below the Barclays level but still implying upside versus the share’s recent Xetra price.

The Barclays call is explicitly linked to Bayer’s deleveraging trajectory, with management now expecting net financial debt of EUR 29 billion to EUR 30 billion by year-end 2026 compared with an earlier forecast range of EUR 32 billion to EUR 33 billion, as highlighted by Ad-hoc-news.

Investor day targets and Apollo transaction underpin guidance

As Ad-hoc-news explains, Bayer’s recent crop science investor day outlined medium-term goals that include improving EBITDA before special items by EUR 1.0 billion and lifting free operating cash flow to more than EUR 3.0 billion by 2029, providing a numerical roadmap that supports the deleveraging narrative.

The same source notes that management has already banked nearly EUR 400 million in cost savings, a tangible portion of the multi-year efficiency program that investors monitor closely when judging whether the group can sustain higher margins and cash generation in its agriculture and pharmaceutical businesses.

A key structural element in Bayer’s balance sheet strategy is the July 2026 agreement with Apollo Global Management, under which Apollo will inject EUR 3.0 billion of equity for a minority stake in a new entity focused on reversible long-acting contraceptives, with Bayer retaining majority control and operational oversight, as detailed by Ad-hoc-news.

First-half 2026 figures show moderate growth

For the first half of 2026, revenue at Bayer reached EUR 24,277.0 million, representing a 3.3 percent increase on an adjusted basis versus the comparable prior-year period, according to figures cited by Ad-hoc-news.

In the same reporting period, EBITDA before special items climbed 6.6 percent to EUR 6,597.0 million, while core earnings per share increased 3.4 percent to EUR 3.66, showing that profitability expanded faster than top-line growth and offering some support for the company’s longer-term margin ambitions, as outlined by Ad-hoc-news.

Management reaffirmed full-year 2026 guidance for adjusted EBITDA in a range of EUR 9,600.0 million to EUR 10,100.0 million and core EPS between EUR 4.30 and EUR 4.90, underscoring that the improved debt forecast arises mainly from stronger cash generation and portfolio measures rather than from a softening of operating targets, as per Ad-hoc-news.

Crop science pipeline news adds to long-term story

Beyond the near-term deleveraging focus, Bayer has highlighted the long-term potential of its crop science pipeline, presenting ten blockbuster candidates with prospects stretching to 2035, including the corn system Preceon and the herbicide Icafolin, according to Goldesel on September 9, 2026.

The same report notes that Bayer shares closed at EUR 49.21 on September 8, 2026, unchanged on the day, and that the stock has gained 33.14 percent since the start of 2026, demonstrating that investors have already priced in a significant portion of the turnaround narrative in both the agricultural and pharmaceutical segments, as indicated by Goldesel.

While the pipeline announcement itself did not trigger a immediate price spike, the combination of medium-term product prospects and improved financial guidance forms a backdrop that helps explain why a bank such as Barclays is willing to set a target more than 40 percent above the current share price, suggesting room for further rerating if execution stays on track.

Roundup-related litigation remains a key risk

Despite the progress on debt and the optimistic analyst calls, legal risk continues to loom over Bayer due to its acquisition of Monsanto and the legacy of the weedkiller Roundup, which is linked to non-Hodgkin lymphoma claims in multiple jurisdictions.

Humana filed a federal complaint on September 3, 2026 seeking recoveries tied to payments for Medicare Advantage members’ non-Hodgkin lymphoma care, targeting Bayer and Monsanto and challenging elements of the USD 7.3 billion settlement structure for Roundup-related cases, as reported by Becker's Payer.

For investors, this lawsuit underscores that, even as Bayer’s operating figures improve and debt guidance is revised downwards, litigation remains a significant overhang that could affect future cash flows and constrain the pace of deleveraging if additional settlements or judgments emerge.

Current price action on Xetra

Intraday data from German market portals on September 9, 2026 show Bayer stock trading around EUR 49.12 on Xetra with a loss of about 0.6 percent compared with the prior close, placing the shares among the weaker names in the DAX 40 in midday trade and illustrating that short-term price fluctuations continue to accompany the longer-term recovery story.